**Induction Maintenance Concept for HAART as Initial Treatment in HIV Infected Infants**

S. Ghosh1, J. Neubert1, T. Nichues2, O. Adams3, N. Morali-Karzel1, A. Borkhardt1, H. J. Laws1

1Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine Universitaet Dusseldorf, Medical Faculty, Duesseldorf, Germany
2Department of Pediatrics, Helios Hospital Krefeld, Krefeld, Germany
3Institute of Virology, Heinrich-Heine Universitaet Dusseldorf, Dusseldorf, Germany

*Both authors contributed equally to this work.*

**Abstract**

**Background:** Early initiated antiretroviral therapy (ART) in HIV infected infants leads to improved long-term viral suppression and survival. Guidelines recommend initiating therapy with a triple ART consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) and either one additional non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI). Compared to older children and adults, viral relapse is seen more frequently in infants receiving triple ART. We now address the possibility of a more potent ART with a quadruple induction and triple maintenance therapy.

**Methods:** We examine the longitudinal course in four HIV infected infants, who were referred from other centers and could not be recruited to multicentre trials. We introduced ART initially consisting of two NRTIs, one NNRTI and one PI and later discontinued the PI at the age of 12 months maintaining a triple regime consisting of two NRTIs and one NNRTI.

**Results:** Provided that therapy adherence was maintained we observed an effective sustained decline of viral load and significant CD4 cell reconstitution even after switching to a triple regime. No drug associated toxicity was seen.

**Conclusion:** We suggest that a four drug therapy might be a possible initial therapy option in HIV infected infants, at least in those with a high viral load, followed by a maintenance triple regime after 12 months of therapy.

**Keywords:** HIV, HAART, anti HIV agents, infants, viral load

**Background**

European [1] and US guidelines [2] recommend to start with ART in all HIV infected infants below the age of 12 months irrespective of clinical or immunological stage. In particular, in infants infected despite attempted mother to child transmission prophylaxis, ART should be commenced as soon as the diagnosis is confirmed. Evidence that early therapy in all infected infants leads to a significant reduction of morbidity and mortality compared to deferring treatment came from CHER trial conducted in South Africa [3] and from the European Infant Collaboration group [4]. In the CHER trial early HIV diagnosis and early treatment reduced early infant mortality by 76%.

Virological failure continues to be a major challenge after initiating early ART in infants. PEnPACT-1 showed recently that in children following the recommended initial regimen with two nucleoside reverse transcriptase inhibitors (NRTI) and one protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) 71% were on first-line ART after a median follow-up time of 5 years, nevertheless only 56% had continued viral load suppression [5]. Previous studies even show that consistent long term viral suppression with HIV-1 RNA below detection limit is achieved in less than 50% of the children with first line triple ART. Children with an increased viral load are at risk for a rapid progression of disease and therapy failure [6, 7]. While this drug combination follows official recommendations [1, 2], several studies have addressed the possibility of introducing a more aggressive initial regime consisting of four antiretroviral drugs [8-13].

Luzuriaga et al studied 52 infants receiving different therapy regimes and demonstrated an improved long-term viral suppression in patients with a quadruple therapy initiated before the age of 3 months [9]. A tolerability and safety study showed low adverse events in children receiving a 4- and 5- drug regimen [10]. Based on these findings and our own experience with standard triple ART we report on four vertically HIV infected children, in whom a quadruple antiretroviral drug scheme was introduced consisting of two NRTIs, one NNRTI and one PI. We furthermore address the possibility of starting with a quadruple therapy in the first year of life and later maintaining a triple regime consisting of two NRTIs and one NNRTI.

**Methods**

**Patients**

Between 2004 and 2009 four infants were initially treated with a quadruple therapy at our HIV outpatient clinic. All were referred to us from other centers. All mothers underwent a caesarean section. In two patients, maternal HIV diagnosis was made at a late stage
of pregnancy, thus transmission prophylaxis to prevent mother to child infection was incomplete. In both children HIV infection was revealed after birth; in patient 1 at the age of 4 weeks, in patient 2 at the age of 5 months. In mothers of patient 3 and 4 a caesarean was performed due to obstetric problems. Maternal HIV was not diagnosed until after birth, when their children were admitted due to repeated watery wasting-syndrome-like diarrhea, failure to thrive and pneumocystis jiroveci pneumonia. For detailed patient characteristics see Table 1. After discharge, patients were followed at least once to twice monthly, before they were switched to a trimonthly interval, once a good viral control was achieved. Prophylaxis of opportunistic infections included trimethoprim-sulfamethoxazole (patients 1, 2, 4), atovaquon (patient 3) and i.v. immunoglobulines (patient 3-4) in the children’s first year of life.

**Antiretroviral Drugs**

In all patients we introduced a regimen consisting of two NRTIs, one NNRTI and one PI. In the light of existing literature that quadruple therapy might have a positive effect on initial viral load without any major adverse consequences our studies strongly conformed to the Helsinki Declaration. Informed consent regarding implementing a quadruple drug regimen and publication of anonymized data was obtained from all parents. In patient 1 resistance testing was carried out, which did not imply any drug restrictions. Antiretroviral drugs used for therapy were given at the following

| Table 1. Patient characteristics. |
|----------------------------------|
| **Patient** | 1 | 2 | 3 | 4 |
| **Mode of delivery** | Caesarean (38th week) | Caesarean (29th week) | Caesarean | Caesarean (41st week) |
| **Prepartal prophylaxis** | ZDV, 3TC, NVP (5 weeks) | None | None | None |
| **Intrapartal prophylaxis** | ZDV | None | None | None |
| **Postnatal prophylaxis** | ZDV (4 weeks) | 2 x NVP; ZDV + 3TC (6 weeks) | None | None |
| **Age at diagnosis** | 4 weeks | 5 months | 2.5 months | 4.5 months |
| **Initial HIV-1 RNA load (copies/ml)** | 500 000 | 16 000 | 139 670 | 3 600 000 |
| **Initial CD4 cell count (absolute cells, μl / %)** | 3732 / 44 | 2515 / 43 | 1093 / 17 | 330 / 6 |
| **Initial CD4 cell count (ARP, %)** | 106 | 100 | 44 | 13 |
| **4 drug HAART** | ABC, 3TC, LPV, NVP | ABC, 3TC, LPV, NVP | ZDV, 3TC, NFV, NVP | ZDV, 3TC, LPV, NVP |
| **Maximal decline of viral load (log change and duration)** | 5 log; 4.5 months | 4 log; 2 months | 5 log; 2 months | 5 log; 6 months |
| **Duration of 4 drug HAART** | 11 months | 13 months | 13 months | 10 months |
| **Clinical toxicity** | *Atopic dermatitis | None | None | None |
| **Laboratory toxicity** | AST (1.4 x ULN - Grade 1); AP (2.2 x ULN - Grade 1); Cholesterol (235 mg/dl - Grade 2); *GGT (18.6 x ULN) | AP (1.4 x ULN - Grade 1); CK (4.2 x ULN - Grade 1); *GGT (2.1 x ULN) | AP (1.2 x ULN - Grade 1); CK (2.2 x ULN - Grade 0); *GGT (7.2 x ULN) | AP (1.8 x ULN - Grade 1); CK (2.4 x ULN - Grade 0); *GGT (27 x ULN); Triglycerides (498 mg/dl - Grade 1) |
| **3 drug HAART** | ABC, 3TC, NVP | ABC, 3TC, NVP | ZDV, 3TC, NVP | ZDV, 3TC, NVP |
| **Viral load at last visit (copies/ml)** | 16801 | <1 | <1 | 48 |
| **Follow up time** | 50 months | 50 months | 34 months | 27.5 months |

Antiretroviral drugs: Abacavir (ABC), Lamivudine (3TC), Lopinavir (LPV), Nelfinavir (NFV), Nevirapine (NVP), Zidovudine (ZDV); Adverse effects were graded according to DAIDS (Division of AIDS, NIH), ULN = upper limit of normal, *no DAIDS criteria; *elevated 4 weeks after switching to a triple drug regime.

Antiretroviral drugs: Abacavir (ABC), Lamivudine (3TC), Lopinavir (LPV), Nelfinavir (NFV), Nevirapine (NVP), Zidovudine (ZDV); Adverse effects were graded according to DAIDS (Division of AIDS, NIH), ULN = upper limit of normal, *no DAIDS criteria; *elevated 4 weeks after switching to a triple drug regime.
daily dosage: twice 180mg of ZDV/m² of body-surface area, twice 150-200mg of NVP/m², twice 300mg of LPV/m² (increased due to addition of NVP), twice 55mg of NFV/kg body weight, twice 8mg of ABC/kg, twice 4mg of 3TC/kg. Adverse effects were graded according to DAIDS (Division of AIDS, NIH) [14]. Therapeutic drug monitoring was applied in patient 1 as viral relapse in this patient suggested malcompliance.

PLASMA HIV-1 RNA, DETERMINATION OF LYMPHOCYTE SUBSETS BY FLOW CYTOMETRY AND LABORATORY ANALYSIS

Plasma viral load was determined by quantitative PCR, the lower limit of detection of the assay was 50 (Quantiplex 3.0 HIV-RNA, Chiron, Fernwald Germany) and 40 (m2000rt RealTime HIV-1 assay, Abbott Laboratories, Abbott Park, IL) HIV1-RNA copies/ml in plasma. CD4 cells were measured with routine flow cytometry (FACScalibur, BD) applying the following conjugated anti-human mAbs: CD8- fluorescein-isothiocyanat, CD4- phycoerythrin, CD3- peridinin chlorophyll protein (Becton Dickinson, Bridgeport, NJ). Absolute CD4 T cell numbers were related to age and age-related percentages (ARP) were calculated as published [15]. Routine clinical chemistry was performed to determine adverse effects according to DAIDS.

RESULTS

Therapy was initiated in four children as seen in Table 1. In all patients quadruple treatment was initiated immediately after they were seen at our department for the first time and diagnosis was made (range: 4 weeks to 5 months). All patients have been seen at our department in regular intervals. Two children have nearly reached the age of five [mean time of follow up: 42 months, range: 27.5 months - 50 months].

VIROLOGICAL RESPONSE

All patients experienced a tremendous decrease of viral load. In all patients we observe a viral load below 500 copies/ml within a mean time of 2.25 months of therapy. All patients had a significant decline in viral load (4-5 log₁₀ within 6 months of therapy) and three patients had a viral load below level of detection within a mean time of two months (Fig. 1). Switching to a triple regime was not followed by a viral relapse. However, in
patient 1 we observed an increased viral load at the age of 20 months. Therapeutic drug monitoring showed that non-compliance has been the major factor for viral failure. In patient 3 we even see a HIV seroreversion as published. Thus all patients remain at the initial antiretroviral regime, as viral load is sustaining.

**Clinical Follow-Up**

Patient 1 and 2 were in a good clinical condition, as the diagnosis was established due to a known maternal HIV infection, while in patients 3 – 4 HIV was diagnosed, when they were admitted due to a critical AIDS-defining condition. After introducing quadruple therapy both patients experienced a profound improvement of the general condition. Till now all patients remain free of further acquired AIDS defining conditions or severe illness.

**ImmuneReconstitutions**

Absolute CD4 cells and CD4 age-related-percentages (see Fig. 1) in patient 1 and 2 have been initially within the estimated range and hence no long-term change was observed. Patient 3 and especially patient 4, suffering from a seriously depleted CD4 cell count (40% and 20% of age-related-percentages), experienced a reconstitution (4.5 months in patient 3, 12 months in patient 4) during the observation period (> 100% age-related-percentage).

**Safety**

Quadruple therapy was well tolerated in all patients. All patients gained weight and height. Patient 1 developed atopic dermatitis; in patient 3 seborrhoic dermatitis, which already begun before ART, was sustained under treatment. We did not observe any major drug toxicity in any patient. A slight elevation of creatine kinase (patient 2,3,4), triglycerides (patient 4), total cholesterol (patient 1), aspartate transaminase (patient 1), alanine transaminase (patient 1), gamma-glutamyl transferase (patient 1,2,3,4) and alkaline phosphatase (patient 1,3,4) were reported. No treatment related adverse clinical or laboratory event grade 3 or 4 was seen while the patients were receiving a four drug combination.

In all patients four antiretroviral drugs for a defined period led to a rapid decline in viral load, which, provided drug compliance was given, sustained for the whole observation time, even after switching to a triple regime. In all patients CD4 cells reconstituted to normal values and all patients were free from AIDS defining conditions afterwards. Even after a mean time of observation of 42 months we did not see any potential long time side effect, which can be attributed to a 4-drug therapy.

**Discussion**

In HIV infected children mortality and disease progression is especially high in infancy [6, 7]. Children with an increased viral load, especially those with an AIDS defining illness, are at risk for rapid progression and death, even after starting ART [6, 7]. Most studies published to date suggest that long term control of viral replication is difficult to achieve in children especially in infants starting early ART. The PENTA 7 study with 20 infants showed a rapid decrease in viral load within four weeks, however only 25% achieved a viral load below the level of detection (20% after 24 weeks of therapy) [6]. A 96-week follow up in the PENTA 7 study shows that only 55% of the children still received the initial ART regimen. Chiappini et al reported on 40 perinatally HIV-infected children receiving HAART with a median follow up of 5.96 years and observed that 77.5% of the early treated children had undetectable viral load at their last visit, however only 47.5% were still receiving their first HAART regimen [17, 18]

Due to this frequently observed virologic failure several studies have addressed the possibility of introducing a more aggressive initial regime consisting of four antiretroviral drugs however only few authors have compared 3- with 4-drug regimens.

Luzuriaga compares three different combinations (ZDV+3TC+NVP vs ZDV+3TC+NVP+abacavir(ABC) vs. 3TC+NVP+ stavudine(D4T)+nelfinavir(NFV)) in children below and above 3 months of age at the time of initiation (n = 52) [9]. A significant difference in an intention-to-treat analysis was seen in week 48 and week 200 between both reverse transcriptase inhibitors only regimen (NRTI and NNRTI) on the one hand and the quadruple drug regimen consisting of a NRTI, a NNRTI and a PI on the other. An increased toxicity was not reported. Studies conducted in adults comparing a triple therapy (2 NRTIs 1 NNRTI) with a quadruple therapy (3 NRTIs 1 NNRTI) did not show any significant difference leading to the conclusion that an additional drug class is required to see any superiority [8, 11].

Starr observed 57 children (range 3.8 to 16.8 years), who were previously treated with NRTIs, switching to a regimen consisting of two NRTIs+NFV+efavirenz (EFV) [12]. No control groups were analyzed. The percentage of patients with a low viral load increased rapidly under the new combination and remained stable from week 8 to week 48. At week 48, the percentage of children with plasma HIV-1 RNA levels of less than 400 copies per milliliter was 81 percent, the absolute percentage of CD4 cells had increased by a median of 3 percent.

Melvin observed 36 children (range 0.2 to 16.0 years) with different previous drug combinations before changing to a four or even five drug regimen [10]. After initiation of the new regimen all children experienced a significant decrease in viral load. The median RNA level at the last follow-up during 4- or 5-drug ART was 1.7 log10, 78% of the children had RNA levels below the level of detection. After a median of 29 months of 4- or 5-drug ART, the median CD4 cell count had an increase by 339 cells/µL. CD4 cell counts improved to or remained at age-appropriate levels in children with a viral load below 50 copies/mL.

In the above mentioned studies the patients were kept on their 4- or 5-drug ART despite achieving undetectable viral load. Since long term side effects of
ART and lack of compliance are an issue especially in infants starting with early ART we initially treated the 4 infants with a quadruple ART consisting of two NRTIs, one NNRTI and one PI and then switched to a triple maintenance therapy with two NRTIs and one NNRTI after achieving significant viral suppression and immune reconstitution. In our patients receiving a quadruple therapy a rapid and significant reduction of viral load was seen within 2 months of therapy. All patients achieved a viral load below < 500 copies/ml within 6 months, in ¾ patients viral load was below detection limit within 2 months. Even after changing to a triple regimen all patients are still on their initial ART regimen and only one patient experiences a viral relapse due to proven malcompliance.

Beside slightly elevated biochemical parameters no grade 3 / 4 toxicity was observed and medication was well-tolerated. In treatment naive infants Luzuriaga described adverse clinical or laboratory events in 8 of 52 patients receiving quadruple therapy (grade 2 (4 patients), grade 3 (1 patient), grade 4 (3 patients)), however these patients were receiving reverse-transcriptase inhibitors only (2 NRTI + 2 NNRTI); while no treatment-related adverse effect was reported among children receiving the regimen including a PI (2 NRTI + 1 NNRTI + 1 PI) [9]. In therapy-experienced children receiving a four drug regimen adverse reactions were limited to mild neutropenia and mild transient elevations in liver enzymes [10]. Starr observed severe effects, consisting of severe neutropenia, hepatic toxicity, diarrhea and rash with fever, in about 10% of the children treated with two NRTIs and two NNRTIs [12].

Though not observed in our patients the addition of another drug class in HIV initial treatment could imply the possibility of further interactions and adverse effects with the co-medication regarding prophylaxis and therapy of opportunistic infections. Inadequate plasma drug levels due to malabsorption or non-adherence lead to development of drug resistance which preserves only few alternatives for further treatment.

We treated four children with a 4 drug combination for 10-13 months. While two children received an incomplete peripartal prophylaxis and were thus pretreated, in two patients HIV was diagnosed during an opportunistic infection. Both subgroups strongly qualified for a virologic relapse. Three out of four patients who were initially treated with a 4 drug combination for 12 months showed sustained virus suppression and did not relapse even after changing to a triple therapy with two NRTI and one NRTI. In one patient who initially had viral load below detection limit after 4.5 months of therapy, viral rebound later occurred and was related to adherence problems, concluding that in all adherent patients viral load remained low. Compared to other studies and our own experience in the past with triple ART, treatment failure and resistance is common on triple ART and was improved on a quadruple drug regimen. Drug toxicity is not increased as seen in our patients. A quadruple induction therapy is still not recommended in all current guidelines, but since a high viral burden and opportunistic infections at the time of diagnosis predict an unfavorable outcome, we strongly support a quadruple therapy in these patients. As we consider that the first year of life represents the most vulnerable phase a 4 drug regime should be maintained for this period. Drug levels and viral load should be monitored at close intervals. Clinical trials with larger pediatric cohorts and different combinations are strongly required to address this question and to provide essentials for a new definition and composition of a "highly active antiretroviral therapy".

Acknowledgements: We thank all referring hospitals and their doctors contributing by sending these patients for further treatment to our department.

Statement of financial support: No financial support was received.

REFERENCES
1. Welte S, Sharland M, Lyall EG, Tudor-Williams G, Nichues T, Wintergerst U, et al. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV med. 2009 Nov;10(10):591-613.
2. Children WGoATaMmO-H. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. February 23, 2009:1-139.
3. Violan A, Cotton MF, Gobin DB, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008 Nov 20;359(21):2233-44.
4. Goetghelue T, Haeltman E, Le Chenadec J, Dolfius C, Gibb D, Judd A, et al. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS (London, England). 2009 Mar 13;23(5):597-604.
5. PENPACT-1 First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. The Lancet infectious diseases. Jan 31.
6. Aboulker JP, Babiker A, Chais Ml, Compagnucci A, Darbyshire J, Debre M, et al. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS (London, England). 2004 Jan 23;18(2):237-45.
7. Shearer WT, Quinn TC, LaRussa P, Lew JF, Mofenson L, Almy S, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med. 1997 May 8;336(19): 1337-42.
8. Gulick RM, Rubai OJ, Shikuma CM, Lala C, Schackman MR, Meyer WA, 3rd, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. Jama. 2006 Aug 16;296(7):769-81.
9. Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med. 2004 Jun 10; 350(24):2471-80.
10. Melvin AJ, Lewis PF, Mohan KM, Naugler WS, Frenkel LM. Efficacy and toxicity of antiretroviral therapy using 4 or more agents: application of a strategy for antiretroviral management in human immunodeficiency virus-infected children. Archives of pediatrics & adolescent medicine. 2002 Jun;156(6):658-73.
11. Orkin C, Stebbings J, Nelson M, Bower M, Johnson M, Mandala S, et al. A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study). J Antimicrob Chemother. 2005 Feb; 55(2): 246-51.
12. Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med. 1999 Dec 16;341(25):1874-81.

13. Tudor-Williams G, Head S, Weigel R, Valerius NH, Ridell A, Lyall EG. Baby Cocktail! A protease-sparing 4 drug combination for symptomatic infants. International Conference on AIDS. 2002 Jun 7-12;14.

14. DAIDS. National Institutes of Health, Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 1.0, 2004. http://www3.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/PDF/DAIDSAEGradingTable.pdf. [cited; available from: http://www3.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/PDF/DAIDSAEGradingTable.pdf]

15. Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Plaeger S, Stiehm ER, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clinical Immunol. 2003 Nov;112(5):973-80.

16. Neubert J, Laws HJ, Adams O, Munk C, Kramer M, Nichues T, et al. HIV-1 seroreversion following antiretroviral therapy in an HIV-infected child initially presenting with acquired immunodeficiency syndrome. AIDS (London, England). Jan 16;24(2):327-8.

17. Chiappini E, Galli L, Tovo PA, Gabiano C, Gattinara GC, Guarino A, et al. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection. AIDS (London, England). 2006 Jan 9;20(2):207-15.

18. Chiappini E, Galli L, Tovo PA, Gabiano C, Lisi C, Bernardi S, et al. Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy. BMC infectious diseases. 2009;9:140.

Received: January 20, 2011 / Accepted: March 30, 2011

Address for correspondence:
Dr. med. Sujal Ghosh, MD
Department of Pediatric Oncology, Hematology and Clinical Immunology
University Hospital Düsseldorf
Medical Faculty, 40225 Düsseldorf
Germany
Tel.: +49-211 8118297
Fax: +49-211 8116539
E-mail: sujal.ghosh@med.uni-duesseldorf.de